Abingdon extends strategic alliance with Stason Pharma

24 November 2008

US firms Abingdon Life Sciences and Stason Pharmaceuticals have extended their strategic alliance announced on August 4, under which the former will utilize the resources of Stason Pharma Japan to enhance its business development and intellectual property licensing opportunities in Asia. Abingdon will also offer strategic planning, clinical development and regulatory science support for companies in Japan and throughout Asia wishing to register pharmaceuticals, biotechnology products and medical devices in the USA via the Japanese unit of Stason.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight